Publication:
Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases

dc.contributor.authorGarcia-Pavia, Pablo (57197883068)
dc.contributor.authorRapezzi, Claudio (7005883289)
dc.contributor.authorAdler, Yehuda (7005992564)
dc.contributor.authorArad, Michael (7004305446)
dc.contributor.authorBasso, Cristina (7004539938)
dc.contributor.authorBrucato, Antonio (7006007796)
dc.contributor.authorBurazor, Ivana (24767517700)
dc.contributor.authorCaforio, Alida L. P (7005166754)
dc.contributor.authorDamy, Thibaud (6506337417)
dc.contributor.authorEriksson, Urs (7102875592)
dc.contributor.authorFontana, Marianna (16306839900)
dc.contributor.authorGillmore, Julian D (7003539031)
dc.contributor.authorGonzalez-Lopez, Esther (56453004900)
dc.contributor.authorGrogan, Martha (7004085182)
dc.contributor.authorHeymans, Stephane (6603326423)
dc.contributor.authorImazio, Massimo (55787131200)
dc.contributor.authorKindermann, Ingrid (6603127742)
dc.contributor.authorKristen, Arnt V (7801324099)
dc.contributor.authorMaurer, Mathew S (35515053700)
dc.contributor.authorMerlini, Giampaolo (7006059649)
dc.date.accessioned2025-06-12T13:33:45Z
dc.date.available2025-06-12T13:33:45Z
dc.date.issued2021
dc.description.abstractCardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice. © The Author(s), 2021.
dc.identifier.urihttps://doi.org/10.1093/eurheartj/ehab072
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85105690396&doi=10.1093%2feurheartj%2fehab072&partnerID=40&md5=2257814ab852d3ad0d52b40431fd1e55
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/4227
dc.subjectAL
dc.subjectAmyloidosis
dc.subjectCardiac amyloidosis
dc.subjectDiagnosis
dc.subjectTransthyretin
dc.subjectTreatment
dc.subjectTTR
dc.titleDiagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases
dspace.entity.typePublication

Files